Codex Genetics was incorporated in 2013 Q1 by scientists specialized in genomics and bioinformatics. Through the use of next generation sequencing, Codex has developed a cancer genetics test using latest seqeuncing technology – GENESIS. Together with our actively growing pharmacogenomics database, we provide valuable insights into the specific causes of each individual tumor, enabling clinicians to personalize treatment for cancer patients during routine oncology practice.
Codex's clinical pharmacogenomics platform helps inform treatment options and predict patients' response to drugs, based on individual genomic information. The differences in genetic makeup between individuals can determine the relative ability to absorp, metabolise and respond to drugs, which ultimately control their effectiveness and side effects. Codex provides two clinically actionable genetic tests that targets Cancer or other FDA approved diseases with proven pharmacogenomic information, allowing clinicians to provide personalised medication in the era of "Precision Medicine".
Our expert team has curated thousands of scientific literatures to identify genes with well-established pharmacogenomics link. Based on latest recommendations from international clinical research consortiums, the comprehensive GENESIS TMpanels can inform clinicians of sensitivity or resistance to FDA approved drugs and treatments under clinical trial.
Utilizing trusted and tried Next Generation Sequencing (NGS) technology,
we are able to profile Single Nucleotide Variations (SNVs), insertions,
deletions, and Copy number variations (CNVs) in one test. On average, each
DNA location is read more 500 times, allowing us to achieve >99% sensitivity
and specificity.
Testing results will be available in ~2 weeks after receiving samples. All the identified molecular alterations will be delivered to the clinicians through our interactive GENESIS TMplatform, and those that are relevant to clinical actions (e.g. Drug sensitivity, resistance) are highlighted. A summary of supporting researches will also be made available.
CEO
Aldrin is a current Ph.D. candidate in the Computational and System Biology Program, Washington University School of Medicine. He received his B.Sc. and M.Phil. degree in Biochemistry from Hong Kong Bioinformatics Center and the School of Life Sciences, The Chinese University of Hong Kong. His researches primarily involves the investigation of the allergenicity of Dust Mite – the predominant source of inhalant allergen with over 50% of world-wide allergic disease cases in clinic being attributed to it, by using a multi-omic approach.
Genetic Scientist
Marco obtained both his B.Sc. & Ph.D. degree of Biochemistry in The Chinese University of Hong Kong, and is currently pursuing MBChB in the same university. His keen interest in bioinformatics and genomic medicine has led him to develop the first algorithm to identify viral-human integration event in cancers, and promote resources for the bioinformatics community. His representing research include the development of ViralFusionSeq bioinformatics tool.
Genetic Scientist
Allen is a postdoctoral fellow in the School of Life Sciences, The Chinese University of Hong Kong. He obtained his B.Sc. degree in Molecular Biotechnology at the Chinese University of Hong Kong in 2009 and Ph.D. in Biochemistry at the same university in 2013. Allen was involved in the identification and characterization of a novel mutation marker causing Spinocerebellar Ataxia, which is a group of diverse neurodegenerative disorders. He is also taking part in the analysis of cancer genome, transcriptome and methylome.
